Real‐World Outcomes of Immune Checkpoint Inhibitors in Melanoma, Including Acral and Mucosal Subtypes: A Retrospective Cohort Study From a Latin American Center
Background Real‐world evidence on immune checkpoint inhibitors (ICIs) in Latin American patients with melanoma remains limited, particularly for acral and mucosal subtypes. We evaluated survival, radiologic response, immune‐related adverse events (irAEs), and exploratory factors associated with outcomes in a Colombian...